Electromed Cash and Equivalents Trend from 2010 to 2020

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>EL</div>
ELMD -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

Electromed Cash and Equivalents is increasing over the years with slightly volatile fluctuation. Ongoing Cash and Equivalents is expected to grow to about 9.2 M this year. During the period from 2010 to 2020 Electromed Cash and Equivalents anual values regression line had geometric mean of 3,072,828 and significance of  0.00000029. Electromed Interest Expense is expected to significantly decrease based on the last few years of reporting. The last year's Interest Expense was at 44,880.3. The current year Net Income is expected to grow to about 3.6 M, whereas Earning Before Interest and Taxes EBIT is expected to decline to about 2.7 M.

Search Historical Trends

 
Refresh
Check Electromed financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Consolidated Income of 2.4 M, Cost of Revenue of 7.5 M or Earning Before Interest and Taxes EBIT of 2.7 M, as well as many exotic indicators such as Asset Turnover of 1.3, Book Value per Share of 2.98 or Current Ratio of 8.78. This can be a perfect complement to check Electromed Valuation or Volatility. It can also complement various Electromed Technical models. Continue to the analysis of Electromed Correlation with competitors.

  Electromed Quarterly Cash and Equivalents

Electromed Cash and Equivalents Marginal Breakdown

Showing smoothed Cash and Equivalents of Electromed with missing and latest data points interpolated. A component of Total Assets representing the amount of currency on hand as well as demand deposits with banks or financial institutions.
View

9.21 M

10 Years Trend
Increasing
Slightly volatile
 Cash and Equivalents 
      Timeline 

Electromed Cash and Equivalents Regression Statistics

Arithmetic Mean 4,710,801
Geometric Mean 3,072,828
Coefficient Of Variation 71.58
Mean Deviation 2,888,209
Median 5,123,355
Standard Deviation 3,371,901
Range 8,848,084
R-Value 0.98
R-Squared 0.95
Significance 0.00000029
Slope 992,200

Electromed Cash and Equivalents Over Time

2010361.9 K
20111.7 M
2012503.6 K
20131.5 M
20143.6 M
20155.1 M
20165.6 M
20177.5 M
20187.8 M
2019M
20209.2 M

Other Fundumenentals of Electromed

About Electromed Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include Electromed income statement, its balance sheet, and the statement of cash flows. Electromed investors use historical funamental indicators, such as Electromed's Cash and Equivalents, to determine how well the company is positioned to perform in the future. Although Electromed investors may use each financial statement separately, they are all related. The changes in Electromed's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Electromed's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Electromed Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Electromed. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 (projected)
Current Assets23.29 M24.54 M28.22 M
Total Assets27.39 M29.4 M33.81 M
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation therapy in pulmonary care for patients of all ages in the United States and internationally. The company was founded in 1992 and is headquartered in New Prague, Minnesota. Electromed operates under Medical Devices classification in USA and is traded on BATS Exchange. It employs 119 people.

Did you try this?

Run Portfolio Anywhere Now

   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Electromed Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Electromed and Edwards Lifesciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to the analysis of Electromed Correlation with competitors. Please also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page